Ceryvyn Therapeutics (ASX:CYV) Net Margin %: -2,371,100.00% (As of Jun. 2025)


What is Ceryvyn Therapeutics Net Margin %?

Ceryvyn Therapeutics ASX:CYV -7.69% Net Margin % is -2,371,100.00% as of Jun. 2025. The stock has 3 warning signs investors should review. Among 939 Biotechnology companies, Ceryvyn Therapeutics ranks worse than 99.57% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Ceryvyn Therapeutics's Net Income for the six months ended in Jun. 2025 was A$-47.42 Mil. Ceryvyn Therapeutics's Revenue for the six months ended in Jun. 2025 was A$0.00 Mil. Therefore, Ceryvyn Therapeutics's net margin for the quarter that ended in Jun. 2025 was -2,371,100.00%.

The historical rank and industry rank for Ceryvyn Therapeutics's Net Margin % or its related term are showing as below:

ASX:CYV' s Net Margin % Range Over the Past 10 Years
Min: -658018.42   Med: -102386.82   Max: -13373.29
Current: -639297.5

ASX:CYV's Net Margin % is ranked worse than
99.57% of 939 companies
in the Biotechnology industry
Industry Median: -88.29 vs ASX:CYV: -639297.50

Ceryvyn Therapeutics  (ASX:CYV) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Ceryvyn Therapeutics Net Margin % Related Terms

Ceryvyn Therapeutics Net Margin % Historical Data

* Premium members only.

The historical data trend for Ceryvyn Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ceryvyn Therapeutics Net Margin % Chart

Ceryvyn Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -65,900.00 -102,386.82 -131,898.14 -176,427.66 -658,018.42

Ceryvyn Therapeutics Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -117,444.58 -166,941.76 -185,986.46 -548,150.00 -2,371,100.00

ASX:CYV vs VRTX, REGN, ALNY: Net Margin % Comparison

For the Biotechnology subindustry, Ceryvyn Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ceryvyn Therapeutics Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ceryvyn Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Ceryvyn Therapeutics's Net Margin % falls into.


Ceryvyn Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Ceryvyn Therapeutics's Net Margin for the fiscal year that ended in Jun. 2025 is calculated as

Net Margin=Net Income (A: Jun. 2025 )/Revenue (A: Jun. 2025 )
=-250.047/0.038
=-658,018.42 %

Ceryvyn Therapeutics's Net Margin for the quarter that ended in Jun. 2025 is calculated as

Net Margin=Net Income (Q: Jun. 2025 )/Revenue (Q: Jun. 2025 )
=-47.422/0.002
=-2,371,100.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of -2,371,100.00% mean?
Ceryvyn Therapeutics (ASX:CYV) has a Net Margin % of -2,371,100.00% as of Jun. 2025. Net margin is the ratio of total net income to net sales. View historical data on Ceryvyn Therapeutics and its competitors. According to the industry distribution chart, Ceryvyn Therapeutics ranks #935 out of 939 companies in the Biotechnology industry, placing it in the top 99.6%.
Is Ceryvyn Therapeutics' Net Margin % too high?
Ceryvyn Therapeutics' current Net Margin % is -2,371,100.00%. Based on the distribution chart, Ceryvyn Therapeutics ranks #935 out of 939 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Ceryvyn Therapeutics' Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ceryvyn Therapeutics ranks #935 out of 939 companies for Net Margin %. This places Ceryvyn Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Ceryvyn Therapeutics and its competitors. Ceryvyn Therapeutics's current Net Margin % is -2,371,100.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ceryvyn Therapeutics stock overvalued right now?
Ceryvyn Therapeutics (ASX:CYV) has a current Net Margin % of -2,371,100.00%. The current Net Margin % is -2,371,100.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Ceryvyn Therapeutics (ASX:CYV), the current Net Margin % is -2,371,100.00% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ceryvyn Therapeutics Business Description

Address C/ Prime Company Compliance, 505 Little Collins Street, Level 9, Melbourne, VIC, AUS, 3000
Opthea Ltd is engaged in researching and developing novel therapeutic products that target Vascular Endothelial Growth Factors (VEGF) C, D, and R3. The Group operates in one industry and two geographical areas, namely biotechnology and healthcare, with operations in Australia and the United States. The company focuses on developing biological therapeutics for eye diseases and is currently developing a novel biologic therapy, OPT-302, for the treatment of eye conditions. Its products are based on an intellectual property portfolio covering VEGF-C, VEGF-D, and VEGF Receptor-3 targets, aimed at treating diseases associated with blood and lymphatic vessel growth and vascular leakage.